Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).
Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).
It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).